Priya Jaisinghani, MD, DABOM

✨With any weight loss method, there is a chance of weight regain after weight loss✨ 🔹Obesity is a chronic, complex, and relapsing disease⚕️🏥🩺 🔹 When treating chronic diseases, we want to stop the progression of the disease and prevent complications✋🏻🛑🚦 (1/x)

Thank you @chrissyfarr and Leah Rosenbaum for making space for an important conversation surrounding the role of GLP-1s in women’s health. Check out my insights 🙏🏻✨

From metabolism to mind—GLP-1s may reshape addiction care. Honored to co-chair this timely #Endo2025 session with Dr. Ashley Shoemaker + expert panelists! #GLP1 #AddictionMedicine #ObesityCare #ScienceToSolutions

Recent expert commentary and the flagship event of the Global Think-Tank signal a long-overdue policy reckoning for chronic liver disease sldthinktank.com/policy_and_ins… #LiverTwitter #SLDthinktank @AASLDtweets @IntDiabetesFed @EASLEUAffairs @ncdalliance @WorldObesity @FattyLiverA

One of the best things about #ENDO2025 is reuniting with colleagues and friends across the country! @scottisaacsmd

🫀💢 PMS isn’t “just hormonal” — it may be a red flag for heart disease. New study: PMS/PMDD linked to 11% ↑ CVD risk. Time to screen earlier, listen better, & lead with science. 💊🩺 #WomensHealth #HeartHealth #PMS #Endocrinology #HealthEquity 🔗 nbcnews.com/news/amp/rcna2…

🔥 Hot from #ADA2025: Can we cut fat & keep lean mass? 💪 The BELIEVE trial (semaglutide + bimagrumab) showed more VAT loss, 🔥83% drop in hsCRP, adiponectin ↑ & better DBP/HbA1c vs semaglutide alone. Game-changer? #GLP1 #ObesityCare #BELIEVE #Endocrinology#ADA2025 #bimagrumab

🔥 Hot off the press: #Lilly expands single-dose #Zepbound options! 💉 12.5 & 15 mg vials available July 7 💰 $499/month via #LillyDirect 📦 Patient shipments start early Aug 👏 win for increased access 🔗 investor.lilly.com/news-releases/…

🚨 Win for #ObesityCare! 🚨 On 6/10 @AmerMedicalAssn passed a resolution to expand AOM coverage & stop insurer rules forcing GLP-1s through third parties. ⛔💉 Faster access for patients, less red tape for providers. Obesity is a disease—let’s treat it like one. 🧬 #advocacy

We renamed a disease—not for science, but for people. 🩺 Proud to co-author the People-First Liver Charter alongside greats in @NaturePortfolio 🔗 nature.com/articles/s4159… Words can heal. Let’s end stigma in MASLD/MASH—across every specialty. 🌍💬

A message from @OMAsocial past PRESIDENT and #OAC board member @DrAngelaFitch: IT IS TIME for #GLP1 #obesity medication pharmaceutical producers to: #betheHERO #betheHERO! Cut the cost to $299 a month and Increase access to care!

@DrJayyy__ is moderating a panel @DigitalHealthNY on the Use of AI in Weight Management & Maintenance

🍽️ Not everyone can choose healthy food — and that’s a public health issue. #FoodInsecurity is deeply linked to #MASLD, as millions face food deserts, ultra-processed options, or high costs that make healthy eating nearly impossible. In this video by @JVLazarus, Chair of the…

#MASLD @DrSandeepRai2 @drshafikuchay @doc_hormone @abm_kamrul @deepduttaendo @DrJayyy__ @LoriShemek @drstak70 @idrlakshmi @Unnikri

💊 #Orforglipron oral small molecule GLP-1 shows: 👉 A1C ↓ up to 1.6% 👉 Weight ↓ up to 7.9% 👉 Safety profile ⬅️ consistent with injectable GLP-1s 📅 Data from ACHIEVE-1 just dropped 👀 Excited for full results at #ADA2025! #GLP1 #T2D #CKMsyndrome investor.lilly.com/node/52266/pdf

BIG news in obesity & diabetes care! I shared my thoughts with @CNN @jechristensen 🙏🏻 Eli Lilly’s oral GLP-1, orforglipron, could be a game-changer: ✅ Oral ✅ No strict pre-med rules ✅ Easier to make = fewer shortages ✅ No refrigeration 🔗amp.cnn.com/cnn/2025/04/17… #GLP1

🚨 Big news in T2D + obesity care! Orforglipron, the 1st oral GLP-1 RA, hit key Phase 3 goals: ✅ A1C ↓ up to 1.6% ⚖️ Weight ↓ up to 15.8 lbs (7.6%) ⭐ 65% hit A1C ≤6.5% No food/water restrictions. Once-daily pill. Game changer? #ACHIEVE1 🔗 tinyurl.com/ykp8xpkd

🚶‍♂️💉 Can GLP-1 RAs improve walking distance in PAD + T2D? 🌎 PAD affects 230M+ people The STRIDE trial explored semaglutide’s impact. 📊 729 patients (median age: 68, 59% BMI <30) 💉 1 mg #semaglutide vs. placebo 📈 +40m walking distance and QoL improvement #ACC25 #lancet

❤️ Breaking News for American Heart Month! ❤️ The SOUL trial brings key insights for diabetes & heart health! ❣️🔥 👥 9,650 participants | 50+ yrs with T2D + ASCVD, CKD, or both 📉 Oral semaglutide ⬇️ MACE by 14%! (HR 0.86) ✅ Now proven cardioprotective! 💬 Thoughts? #ACC25

This looks so good!! And so many of my favs are on this panel! 👏🏻👏🏻 @BevTchangMD @DrJayyy__ @NeilFlochMD @DrAngelaFitch

I promise it will be entertaining because I will be moderating ⁦@tristateobesity⁩ - a free dinner event on 4/10 6-8PM ET in Connecticut with an expert panel on the #Business of #Obesity #Medicine @NeilFlochMD @DrAngelaFitch @devika_md @DrJayyy__ tristateobesitysociety.org/event-details-…